[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: RLS Protein Subunit Vaccine against SARS-CoV-2 Virus: This Phase I dose determining study will evaluate following three doses for which volume of vaccine administration will be the same i.e. 0.5 ml: -First dose level (Antigenic Content: 2.5 \u00ce\u00bcg of Receptor Binding Domain + 2.5 \u00ce\u00bcg of Nucleocapsid); -Second dose level (Antigenic Content: 5 \u00ce\u00bcg of Receptor Binding Domain + 5 \u00ce\u00bcg of Nucleocapsid) and -Third dose level (Antigenic Content: 10 \u00ce\u00bcg of Receptor Binding Domain + 10 \u00ce\u00bcg of Nucleocapsid).Control Intervention1: Not Applicable: Not Applicable", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: RLS Protein Subunit Vaccine against SARS-CoV-2 Virus: This Phase I dose determining study will evaluate following three doses for which volume of vaccine administration will be the same i.e. 0.5 ml: -First dose level (Antigenic Content: 2.5 \u00ce\u00bcg of Receptor Binding Domain + 2.5 \u00ce\u00bcg of Nucleocapsid); -Second dose level (Antigenic Content: 5 \u00ce\u00bcg of Receptor Binding Domain + 5 \u00ce\u00bcg of Nucleocapsid) and -Third dose level (Antigenic Content: 10 \u00ce\u00bcg of Receptor Binding Domain + 10 \u00ce\u00bcg of Nucleocapsid).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Not Applicable: Not Applicable", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2170, "treatment_name": "Recombinant sars-cov-2 vaccine (rls)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]